-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chinese State Drug Administration Bureau Center for Drug Evaluation (CDE) public display, Roche (Roche) under development RO7247669 injection has been declared clinically in China, and on July 2 were entertained
.
Public information shows that RO7247669 is a bispecific antibody targeting PD-1 and LAG-3 , and Phase 1/2 clinical trials are being carried out worldwide
Management RO7247669 is a bispecific antibody targeting PD-1 and LAG-3
Bispecific antibody is an antibody that can specifically bind to two different antigens
.
This type of therapy uses T cells in the patient’s immune system to kill tumors.
immunity
RO7247669 is a bispecific antibody targeting PD-1 and LAG-3 developed by Roche
.
The PD-1/PD-L1 immune checkpoint is a star target in the field of cancer immunotherapy and is well known to everyone
LAG-3 is called lymphocyte activation gene-3.
It is an immune checkpoint protein expressed on the surface of effector T cells and regulatory T cells (Tregs), which can regulate the signals of T lymphocytes and antigen presenting cells (APCs).
The pathway plays an important role in the adaptive immune response
.
LAG-3 and PD-1 mediate different signaling pathways, but they may have a synergistic effect, leading to depletion of effector T cells
LAG-3 and PD-1 mediate different signaling pathways, but they may have a synergistic effect, leading to depletion of effector T cells
Clinicaltrials.
gov website publicity information display, Roche is carrying out clinical trials to assess the safety and efficacy of RO7247669 indications covered include metastatic melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, advanced liver cancer and so on
.
According to the information on the CDE website, this is the first clinical application for RO7247669 in China
Metastatic melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, advanced liver cancer in this message